Protecting the immune system in ITS fight against cancer

Protecting the immune system in ITS fight against cancer

Protecting the immune system in ITS fight against cancer

Protecting the immune system in ITS fight against cancer

We're creating therapies to disarm cancer’s defenses against the immune system—helping the body’s own T-cells survive, get inside tumors, and fight cancer.

Explore The Science

Explore The Science

Explore The Science

Explore The Science

Introduction

We're unlocking the immune system’s full power against cancer with a first-in-class immunotherapy.

Gamma Biotherapeutics is a private, clinical‑stage biotechnology company discovering and developing therapeutics that help the immune system fight cancer. Our strength lies where novel drug discovery meets clinical development.

Our lead program M3T01 is advancing through a phase I clinical trial in patients with advanced cancers. It represents a bold step toward changing how the immune system can overcome cancer's defenses.

EXPLORE THE TRIAL

EXPLORE THE TRIAL

EXPLORE THE TRIAL

Our Science

Winning the fight against immune evasion

For decades, Fas Ligand (FasL) has been an unsolved challenge in cancer immunology, silently destroying the body's T cells and limiting the promise of immunotherapy.

Gamma Biotherapeutics has pioneered the first FasL-neutralizing monoclonal antibody to enter clinical trials, opening a new frontier in immune‑based cancer treatment.

Explore The Science

Explore The Science

Explore The Science

The Problem
Fas Ligand kills the body’s cancer‑fighting T cells.

Many tumors produce FasL. When activated T cells encounter FasL, a self-destruct program (apoptosis) is initiated and they die before they can eliminate cancer cells.

Laern More

The Problem
Fas Ligand kills the body’s cancer‑fighting T cells.

Many tumors produce FasL. When activated T cells encounter FasL, a self-destruct program (apoptosis) is initiated and they die before they can eliminate cancer cells.

Laern More

The Problem
Fas Ligand kills the body’s cancer‑fighting T cells.

Many tumors produce FasL. When activated T cells encounter FasL, a self-destruct program (apoptosis) is initiated and they die before they can eliminate cancer cells.

Laern More

The Problem
Fas Ligand kills the body’s cancer‑fighting T cells.

Many tumors produce FasL. When activated T cells encounter FasL, a self-destruct program (apoptosis) is initiated and they die before they can eliminate cancer cells.

Laern More

The Breakthrough
Potent FasL blockade.

By shielding T cells from FasL-mediated cell death, M3T01 helps T cells survive, infiltrate tumors, and fight cancer cells.

Laern More

The Breakthrough
Potent FasL blockade.

By shielding T cells from FasL-mediated cell death, M3T01 helps T cells survive, infiltrate tumors, and fight cancer cells.

Laern More

The Breakthrough
Potent FasL blockade.

By shielding T cells from FasL-mediated cell death, M3T01 helps T cells survive, infiltrate tumors, and fight cancer cells.

Laern More

The Breakthrough
Potent FasL blockade.

By shielding T cells from FasL-mediated cell death, M3T01 helps T cells survive, infiltrate tumors, and fight cancer cells.

Laern More

Combination Therapy Ready
Built to integrate with existing immunotherapies.

Because FasL is a distinct immunosuppressive pathway, M3T01 is being evaluated both as a single agent and in combination with immune checkpoint inhibitors such as pembrolizumab and other anti‑cancer therapies..

Laern More

Combination Therapy Ready
Built to integrate with existing immunotherapies.

Because FasL is a distinct immunosuppressive pathway, M3T01 is being evaluated both as a single agent and in combination with immune checkpoint inhibitors such as pembrolizumab and other anti‑cancer therapies..

Laern More

Combination Therapy Ready
Built to integrate with existing immunotherapies.

Because FasL is a distinct immunosuppressive pathway, M3T01 is being evaluated both as a single agent and in combination with immune checkpoint inhibitors such as pembrolizumab and other anti‑cancer therapies..

Laern More

Combination Therapy Ready
Built to integrate with existing immunotherapies.

Because FasL is a distinct immunosuppressive pathway, M3T01 is being evaluated both as a single agent and in combination with immune checkpoint inhibitors such as pembrolizumab and other anti‑cancer therapies..

Laern More

Trial Progress
Now enrolling patients.

A Phase 1, first‑in‑human clinical trial of M3T01 in patients with advanced solid tumors is actively enrolling at Providence Cancer Institute in Portland, Oregon. The study includes both monotherapy dose‑escalation and combination cohorts. Visit our Pipeline page for a full overview and trial details.

Laern More

Trial Progress
Now enrolling patients.

A Phase 1, first‑in‑human clinical trial of M3T01 in patients with advanced solid tumors is actively enrolling at Providence Cancer Institute in Portland, Oregon. The study includes both monotherapy dose‑escalation and combination cohorts. Visit our Pipeline page for a full overview and trial details.

Laern More

Trial Progress
Now enrolling patients.

A Phase 1, first‑in‑human clinical trial of M3T01 in patients with advanced solid tumors is actively enrolling at Providence Cancer Institute in Portland, Oregon. The study includes both monotherapy dose‑escalation and combination cohorts. Visit our Pipeline page for a full overview and trial details.

Laern More

Trial Progress
Now enrolling patients.

A Phase 1, first‑in‑human clinical trial of M3T01 in patients with advanced solid tumors is actively enrolling at Providence Cancer Institute in Portland, Oregon. The study includes both monotherapy dose‑escalation and combination cohorts. Visit our Pipeline page for a full overview and trial details.

Laern More

Why It Matters

Accelerating a Cancer-Free Tomorrow

Preserves T cells

Neutralizing FasL protects activated T cells from apoptosis so they can continue targeting tumor cells.

Enables tumor entry

Counters tumor‑promoting signals

Engineered for specificity

Preserves T cells

Neutralizing FasL protects activated T cells from apoptosis so they can continue targeting tumor cells.

Enables tumor entry

Counters tumor‑promoting signals

Engineered for specificity

Protects T cells

Neutralizing FasL protects activated T cells from apoptosis so they can continue targeting tumor cells.

Enables tumor entry

Counters tumor‑promoting signals

Engineered for stability

Protects T cells

Neutralizing FasL protects activated T cells from apoptosis so they can continue targeting tumor cells.

Enables tumor entry

Counters tumor‑promoting signals

Engineered for stability

Protects T cells

Neutralizing FasL protects activated T cells from apoptosis so they can continue targeting tumor cells.

Enables tumor entry

Counters tumor‑promoting signals

Engineered for stability

Our Team

Led by Matthew Taylor, M.D., our team has expertise bridging the gap between the bench and the bedside, united by one goal: protect the immune system so patients can live cancer-free.

View Team

View Team

View Team

View Team

Purpose in perspective

  • Blocking fas ligand protects T cells and allows them to survive within the hostile environment of tumors. This innovative approach may provide a new therapeutic strategy to enhance the efficacy of cancer immunotherapies.

    - Walter J. Urba, MD, PhD, Emeritus Member, Providence Cancer Institute & Earle A. Chiles Research Institute

  • Blocking fas ligand protects T cells and allows them to survive within the hostile environment of tumors. This innovative approach may provide a new therapeutic strategy to enhance the efficacy of cancer immunotherapies.

    - Walter J. Urba, MD, PhD, Emeritus Member, Providence Cancer Institute & Earle A. Chiles Research Institute